IDEAYA's Darovasertib Hits Primary Endpoint, RTOR Acceptance De-risks Regulatory Path

What happened

IDEAYA announced positive pivotal data for darovasertib in 1L HLA-A2-negative metastatic uveal melanoma, with the Phase 2/3 OptimUM-02 trial meeting its primary endpoint. The FDA has accepted the NDA into the RTOR program, with a pre-submission in May and filing expected in H2 2026, de-risking the regulatory pathway. However, the company remains pre-commercial with no approved products and a $3B market cap trading at a significant premium to its ~$1.1B cash base. Recent partner exits, including GSK and Amgen, highlight competitive and strategic risk, even as darovasertib moves closer to potential approval. The positive data is a major catalyst, but the binary nature of biotech and the lack of diversified revenue means the stock remains highly speculative.

Implication

Darovasertib's path to market is now clearer, supporting a shift to POTENTIAL BUY. Investors should monitor ASCO presentation, NDA acceptance, and subsequent approval for a re-rating.

Thesis delta

The positive data and RTOR acceptance significantly de-risk darovasertib's regulatory path, increasing the probability of near-term approval. However, valuation already reflects this optimism, and execution risks in manufacturing, commercial launch, and synthetic lethality pipeline remain. We upgrade from WAIT to POTENTIAL BUY, but only for high-risk-tolerant investors; price and further data will determine full commitment.